SIRT3 was found to be overexpressed in DLBCL where it was linked to inferior clinical outcomes, and DLBCL cells were observed to be dependent on SIRT3 for their proliferation, survival and self-renewal. The gene discussed is SIRT3; the disease is diffuse large B-cell lymphoma.